Praxis Precision Medicines (PRAX) Current Deferred Revenue (2022 - 2024)
Historic Current Deferred Revenue for Praxis Precision Medicines (PRAX) over the last 3 years, with Q3 2024 value amounting to $1.2 million.
- Praxis Precision Medicines' Current Deferred Revenue fell 2461.34% to $1.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.2 million, marking a year-over-year decrease of 2461.34%. This contributed to the annual value of $1.4 million for FY2023, which is 5060.33% down from last year.
- Latest data reveals that Praxis Precision Medicines reported Current Deferred Revenue of $1.2 million as of Q3 2024, which was down 2461.34% from $1.2 million recorded in Q2 2024.
- In the past 5 years, Praxis Precision Medicines' Current Deferred Revenue ranged from a high of $2.8 million in Q4 2022 and a low of $1.2 million during Q3 2024
- Over the past 3 years, Praxis Precision Medicines' median Current Deferred Revenue value was $1.5 million (recorded in 2023), while the average stood at $1.7 million.
- The largest annual percentage gain for Praxis Precision Medicines' Current Deferred Revenue in the last 5 years was 2461.34% (2024), contrasted with its biggest fall of 5060.95% (2024).
- Quarter analysis of 3 years shows Praxis Precision Medicines' Current Deferred Revenue stood at $2.8 million in 2022, then plummeted by 50.6% to $1.4 million in 2023, then decreased by 15.95% to $1.2 million in 2024.
- Its Current Deferred Revenue was $1.2 million in Q3 2024, compared to $1.2 million in Q2 2024 and $1.3 million in Q1 2024.